Logo image of AVXL

ANAVEX LIFE SCIENCES CORP (AVXL) Stock Fundamental Analysis

NASDAQ:AVXL - Nasdaq - US0327973006 - Common Stock - Currency: USD

10.79  +0.22 (+2.08%)

After market: 10.6101 -0.18 (-1.67%)

Fundamental Rating

3

Taking everything into account, AVXL scores 3 out of 10 in our fundamental rating. AVXL was compared to 555 industry peers in the Biotechnology industry. While AVXL has a great health rating, there are worries on its profitability. AVXL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AVXL has reported negative net income.
In the past year AVXL has reported a negative cash flow from operations.
In the past 5 years AVXL always reported negative net income.
AVXL had a negative operating cash flow in each of the past 5 years.
AVXL Yearly Net Income VS EBIT VS OCF VS FCFAVXL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

AVXL has a Return On Assets of -40.24%. This is comparable to the rest of the industry: AVXL outperforms 56.40% of its industry peers.
AVXL has a Return On Equity of -47.26%. This is in the better half of the industry: AVXL outperforms 66.49% of its industry peers.
Industry RankSector Rank
ROA -40.24%
ROE -47.26%
ROIC N/A
ROA(3y)-31.3%
ROA(5y)-38.71%
ROE(3y)-34.3%
ROE(5y)-44.93%
ROIC(3y)N/A
ROIC(5y)N/A
AVXL Yearly ROA, ROE, ROICAVXL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

AVXL does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVXL Yearly Profit, Operating, Gross MarginsAVXL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for AVXL has been increased compared to 1 year ago.
AVXL has more shares outstanding than it did 5 years ago.
AVXL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AVXL Yearly Shares OutstandingAVXL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AVXL Yearly Total Debt VS Total AssetsAVXL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 26.97 indicates that AVXL is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 26.97, AVXL belongs to the top of the industry, outperforming 95.14% of the companies in the same industry.
AVXL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 26.97
ROIC/WACCN/A
WACCN/A
AVXL Yearly LT Debt VS Equity VS FCFAVXL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 6.74 indicates that AVXL has no problem at all paying its short term obligations.
With a decent Current ratio value of 6.74, AVXL is doing good in the industry, outperforming 65.05% of the companies in the same industry.
AVXL has a Quick Ratio of 6.74. This indicates that AVXL is financially healthy and has no problem in meeting its short term obligations.
AVXL has a better Quick ratio (6.74) than 65.41% of its industry peers.
Industry RankSector Rank
Current Ratio 6.74
Quick Ratio 6.74
AVXL Yearly Current Assets VS Current LiabilitesAVXL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

AVXL shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.00%.
EPS 1Y (TTM)-10%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 94.83% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-13.12%
EPS Next 2Y117.26%
EPS Next 3Y110.2%
EPS Next 5Y94.83%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVXL Yearly Revenue VS EstimatesAVXL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B 4B 5B
AVXL Yearly EPS VS EstimatesAVXL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10 15 20 25

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

AVXL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 7.63 indicates a rather cheap valuation of AVXL.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AVXL indicates a rather cheap valuation: AVXL is cheaper than 97.48% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 21.90. AVXL is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 7.63
AVXL Price Earnings VS Forward Price EarningsAVXL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVXL Per share dataAVXL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as AVXL's earnings are expected to grow with 110.20% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y117.26%
EPS Next 3Y110.2%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AVXL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANAVEX LIFE SCIENCES CORP

NASDAQ:AVXL (7/3/2025, 7:03:34 PM)

After market: 10.6101 -0.18 (-1.67%)

10.79

+0.22 (+2.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners37.6%
Inst Owner Change6.63%
Ins Owners3.29%
Ins Owner Change9%
Market Cap921.14M
Analysts82.22
Price Target43.82 (306.12%)
Short Float %30.54%
Short Ratio28.92
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.15%
Min EPS beat(2)15.03%
Max EPS beat(2)19.26%
EPS beat(4)4
Avg EPS beat(4)16.12%
Min EPS beat(4)14.22%
Max EPS beat(4)19.26%
EPS beat(8)7
Avg EPS beat(8)13.96%
EPS beat(12)9
Avg EPS beat(12)10.21%
EPS beat(16)11
Avg EPS beat(16)9.33%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)19.43%
PT rev (3m)19.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)10.2%
EPS NY rev (1m)8.95%
EPS NY rev (3m)9.42%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 7.63
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 9.23
P/tB 9.23
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)1.41
Fwd EY13.11%
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0
BVpS1.17
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.24%
ROE -47.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.3%
ROA(5y)-38.71%
ROE(3y)-34.3%
ROE(5y)-44.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.74
Quick Ratio 6.74
Altman-Z 26.97
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-13.12%
EPS Next 2Y117.26%
EPS Next 3Y110.2%
EPS Next 5Y94.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year369.85%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-17.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.47%
OCF growth 3YN/A
OCF growth 5YN/A